US EditionPublished • loading... • Updated
T-Maximum Pharmaceutical's Allogeneic Car-T Therapy Mt027 Receives Fda Ind Approval and Will Begin Phase Ii Clinical Trial for Recurrent Glioblastoma – Dir Hongkong
Summary by dirhongkong.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
(SeaPRwire) – Beijing, December 21, 2025 — T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic B7-H3 targeted CAR-T therapy MT027 has received Investigational New Drug (IND) designation from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for recurrent glioblastoma (rGBM). This milestone marks a significant breakthrough in tackling one of the most challenging aspects of oncology – developing effec…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
